Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) m

SOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),

IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative

IDEAYA Presentations:2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma

SOUTH SAN FRANCISCO, Calif., July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA),

SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),

SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS

IDEAYA Biosciences maintains a "Strong Buy" rating, driven by positive darovasertib data in uveal me

SOUTH SAN FRANCISCO, Calif., June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) t

U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak e

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants PR Newswir

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) tod

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) to

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial

Darovasertib combination resulted in a statistically significant and clinically meaningful improveme

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUT

SOUTH SAN FRANCISCO, Calif., May 29, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a

IDEAYA Biosciences NASDAQ: IDYA executives highlighted recent clinical progress across the company's

SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a

IDEAYA Biosciences NASDAQ: IDYA Chief Executive Yujiro Hata said the precision oncology company is p

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline

Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durabil

  During Thursday, 849 stocks hit new 52-week lows.

  Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quart

    Tuesday's session saw 729 companies set new 52-week lows.

    On Friday, 368 stocks hit new 52-week lows.

    Wednesday's session saw 107 companies set new 52-week lows.

    During Tuesday's trading, 505 companies set new 52-week lows.

    On Friday, 313 companies hit new 52-week lows.

    On Thursday, 147 companies achieved new lows for the year.

    On Wednesday, 115 companies reached new 52-week lows.

  During Thursday's morning trading, 152 companies set new 52-week lows.

    During Wednesday's morning trading, 400 companies set new 52-week lows.

    This morning 263 companies set new 52-week highs.

    On Monday morning, 415 companies achieved new highs for the year.

  On Thursday morning, 420 companies hit new 52-week highs.

    This morning 270 companies set new 52-week highs.

    This morning 533 companies reached new 52-week highs.

    Monday morning saw 558 companies set new 52-week highs.

    Before 10 a.m. ET on Wednesday, 375 companies hit new 52-week highs.